Literature DB >> 1706409

Identification of linear epitopes on Semliki Forest virus E2 membrane protein and their effectiveness as a synthetic peptide vaccine.

A Snijders1, B J Benaissa-Trouw, T A Oosterlaken, W C Puijk, W P Posthumus, R H Meloen, W A Boere, J D Oosting, C A Kraaijeveld, H Snippe.   

Abstract

Semliki Forest virus (SFV) infection of mice was used as a model to study the applicability of synthetic peptides containing only linear epitopes as viral vaccines. The identification of linear epitopes with vaccine potential on the E2 membrane protein of SFV was based on the binding of SFV-specific antibodies to a set of overlapping synthetic hexapeptides (Pepscan) representing the whole E2 amino acid sequence. The 14 available E2-specific monoclonal antibodies which were protective in vivo proved to be unsuitable for the identification of linear epitopes because they recognized only conformational epitopes, as indicated by their lack of reactivity with unfolded, reduced E2 protein on immunoblots. Three epitopes were detected with polyclonal anti-SFV serum at amino acid positions 135 to 141, 177 to 185 and 240 to 246 of the E2 protein. Synthetic peptides containing these epitopes were coupled to a carrier protein and tested as a vaccine. Mice immunized with the peptide containing amino acids 240 to 255 of protein E2 were protected against a challenge with virulent SFV but protection of mice immunized with the peptides containing amino acids 126 to 141 or 178 to 186 was only marginally better than that of controls. The prechallenge sera of most peptide-immunized mice reacted with SFV-infected cells but none of these sera neutralized the virus in vitro. However, protection of mice correlated well with SFV-specific antibody titre, suggesting antibody-mediated protection.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1706409     DOI: 10.1099/0022-1317-72-3-557

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  12 in total

1.  Interactions between the transmembrane segments of the alphavirus E1 and E2 proteins play a role in virus budding and fusion.

Authors:  Mathilda Sjöberg; Henrik Garoff
Journal:  J Virol       Date:  2003-03       Impact factor: 5.103

2.  Suppressors of cleavage-site mutations in the p62 envelope protein of Semliki Forest virus reveal dynamics in spike structure and function.

Authors:  I Tubulekas; P Liljeström
Journal:  J Virol       Date:  1998-04       Impact factor: 5.103

3.  Topology of the outer membrane phospholipase A of Salmonella typhimurium.

Authors:  K B Merck; H de Cock; H M Verheij; J Tommassen
Journal:  J Bacteriol       Date:  1997-06       Impact factor: 3.490

4.  The amino acids 736-761 of the MERS-CoV spike protein induce neutralizing antibodies: implications for the development of vaccines and antiviral agents.

Authors:  Yang Yang; Yao Deng; Bo Wen; Huijuan Wang; Xin Meng; Jiaming Lan; George F Gao; Wenjie Tan
Journal:  Viral Immunol       Date:  2014-12       Impact factor: 2.257

5.  Role of γδ T cells in antibody production and recovery from SFV demyelinating disease.

Authors:  Farinaz Safavi; Jason P Feliberti; Cedric S Raine; Foroozan Mokhtarian
Journal:  J Neuroimmunol       Date:  2011-05-25       Impact factor: 3.478

6.  First peptide vaccine providing protection against viral infection in the target animal: studies of canine parvovirus in dogs.

Authors:  J P Langeveld; J I Casal; A D Osterhaus; E Cortés; R de Swart; C Vela; K Dalsgaard; W C Puijk; W M Schaaper; R H Meloen
Journal:  J Virol       Date:  1994-07       Impact factor: 5.103

7.  IgVH determined genetic restriction of a non-internal image monoclonal anti-idiotypic vaccine against Semliki Forest virus.

Authors:  T A Oosterlaken; M Harmsen; G L Ekstijn; C A Kraaijeveld; H Snippe
Journal:  Immunology       Date:  1992-02       Impact factor: 7.397

8.  Influence of epitope polarity and adjuvants on the immunogenicity and efficacy of a synthetic peptide vaccine against Semliki Forest virus.

Authors:  I M Fernández; A Snijders; B J Benaissa-Trouw; M Harmsen; H Snippe; C A Kraaijeveld
Journal:  J Virol       Date:  1993-10       Impact factor: 5.103

9.  A delayed-type hypersensitivity-inducing T-cell epitope of Semliki Forest virus mediates effective T-helper activity for antibody production.

Authors:  A Snijders; B J Benaissa-Trouw; H J Visser-Vernooy; I Fernandez; H Snippe; C A Kraaijeveld
Journal:  Immunology       Date:  1992-11       Impact factor: 7.397

10.  An antibody- and synthetic peptide-defined rubella virus E1 glycoprotein neutralization domain.

Authors:  J S Wolinsky; E Sukholutsky; W T Moore; A Lovett; M McCarthy; B Adame
Journal:  J Virol       Date:  1993-02       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.